{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459811747
| IUPAC_name = (1''S'',3''S'',5''S'')-2-[(2''S'')-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
| image = Saxagliptin structure.svg

<!--Clinical data-->
| tradename = Onglyza
| Drugs.com = {{drugs.com|CDI|saxagliptin}}
| MedlinePlus = a610003
| licence_EU = Onglyza
| licence_US = Saxagliptin
| pregnancy_category =  
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = ~75% (T<small>max</small>（峰值） = 2小时)
| protein_bound = 可忽略不计
| metabolism = 肝脏([[CYP3A4|CYP3A4]]和[[CYP3A5|CYP3A5]])
| elimination_half-life = 2.5 小时 (沙格列汀), 3.1 小时 (主要代谢产物)  
| excretion = 22% ([[胆汁|胆汁]]), 75% ([[尿液|尿液]])

<!--Identifiers-->
| IUPHAR_ligand = 6316
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 361442-04-8
| ATC_prefix = A10
| ATC_suffix = BH03
| PubChem = 11243969
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06335
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9419005
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 8I7IO46IVQ
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 385517

<!--Chemical data-->
| C=18 | H=25 | N=3 | O=2 
| molecular_weight = 315.41 [[Gram|g]]/[[Mole_(unit)|mol]]
| smiles = O=C(N1[C@H](C#N)C[C@@H]2C[C@H]12)[C@@H](N)C35CC4CC(C3)CC(O)(C4)C5
| InChI = 1/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
| InChIKey = QGJUIPDUBHWZPV-SGTAVMJGBR
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QGJUIPDUBHWZPV-SGTAVMJGSA-N
}}

'''沙格列汀（{{lang-en|Saxagliptin}}'''），商品名为'''安立泽'''，是一种[[二肽基肽酶-4抑制剂|二肽基肽酶-4抑制剂]]类口服[[抗糖尿病药|抗糖尿病药]]。<ref name="ahren">{{cite journal | author = Augeri D
 | title = Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
 | journal = [[Journal_of_Medicinal_Chemistry|Journal of Medicinal Chemistry]] | volume = 48 | issue = 15 | pages = 5025–5037 | year = 2005
 | pmid = 16033281| doi = 10.1021/jm050261p| author2 = and others
 | displayauthors = 1
 }}</ref>沙格列汀早期由[[百时美施贵宝|百时美施贵宝]]单独研发，2007年，[[阿斯利康制药|阿斯利康制药]]也加入了研发并共同负责销售。<ref name="Bloomberg">{{cite news| url=http://www.bloomberg.com/apps/news?pid=20601103&sid=amRAcE.Jql6g&refer=news | work=Bloomberg | title=Bristol, Takeda Drugs Offer Alternatives to Januvia (Update2) | date=2008-06-07}}</ref>

2014年2月，基于一篇在新英格兰医学杂志发表的文章，[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）宣布他们正在调查沙格列汀可能会导致的心脏病发病风险。<ref>http://www.webmd.com/diabetes/news/20140211/fda-to-investigate-diabetes-drug-saxagliptin-for-possible-heart-failure-risk</ref><ref name=Sci2013>{{cite journal|last=Scirica|first=BM|author2=Bhatt, DL; Braunwald, E; Steg, PG; Davidson, J; Hirshberg, B; Ohman, P; Frederich, R; Wiviott, SD; Hoffman, EB; Cavender, MA; Udell, JA; Desai, NR; Mosenzon, O; McGuire, DK; Ray, KK; Leiter, LA; Raz, I; the SAVOR-TIMI 53 Steering Committee and, Investigators|title=Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus|journal=The New England Journal of Medicine|date=Oct 3, 2013|volume=369|issue=14|pages=1317–1326|pmid=23992601|doi=10.1056/nejmoa1307684}}</ref> 文章总结指出，DPP-4抑制剂不会增加或减少缺血的发生几率，虽然因[[心力衰竭|心力衰竭]]而[[入院治疗|入院治疗]]的几率有所增加。即使沙格列汀可以控制血糖，但是需要为伴有心血管疾病的糖尿病人增加其他治疗手段，防止心血管疾病发病风险的提高。

百时美施贵宝否认沙格列汀会导致心血管疾病风险增加，并且称沙格列汀非常安全。

==引用==
{{reflist}}

{{口服降糖药和胰岛素类似物}}
{{Diabetes}}

[[Category:腈|Category:腈]]
[[Category:百时美施贵宝|Category:百时美施贵宝]]
[[Category:醇|Category:醇]]
[[Category:酰胺|Category:酰胺]]
[[Category:含氮雜環|Category:含氮雜環]]